Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology - PubMed (original) (raw)

Practice Guideline

. 2018 Aug 1;36(22):2326-2347.

doi: 10.1200/JCO.2018.78.8687. Epub 2018 May 21.

William Dale 1, Mark R Somerfield 1, Mara A Schonberg 1, Cynthia M Boyd 1, Peggy S Burhenn 1, Beverly Canin 1, Harvey Jay Cohen 1, Holly M Holmes 1, Judith O Hopkins 1, Michelle C Janelsins 1, Alok A Khorana 1, Heidi D Klepin 1, Stuart M Lichtman 1, Karen M Mustian 1, William P Tew 1, Arti Hurria 1

Affiliations

Practice Guideline

Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology

Supriya G Mohile et al. J Clin Oncol. 2018.

Abstract

Purpose To provide guidance regarding the practical assessment and management of vulnerabilities in older patients undergoing chemotherapy. Methods An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the medical literature. Results A total of 68 studies met eligibility criteria and form the evidentiary basis for the recommendations. Recommendations In patients ≥ 65 years receiving chemotherapy, geriatric assessment (GA) should be used to identify vulnerabilities that are not routinely captured in oncology assessments. Evidence supports, at a minimum, assessment of function, comorbidity, falls, depression, cognition, and nutrition. The Panel recommends instrumental activities of daily living to assess for function, a thorough history or validated tool to assess comorbidity, a single question for falls, the Geriatric Depression Scale to screen for depression, the Mini-Cog or the Blessed Orientation-Memory-Concentration test to screen for cognitive impairment, and an assessment of unintentional weight loss to evaluate nutrition. Either the CARG (Cancer and Aging Research Group) or CRASH (Chemotherapy Risk Assessment Scale for High-Age Patients) tools are recommended to obtain estimates of chemotherapy toxicity risk; the Geriatric-8 or Vulnerable Elders Survey-13 can help to predict mortality. Clinicians should use a validated tool listed at ePrognosis to estimate noncancer-based life expectancy ≥ 4 years. GA results should be applied to develop an integrated and individualized plan that informs cancer management and to identify nononcologic problems amenable to intervention. Collaborating with caregivers is essential to implementing GA-guided interventions. The Panel suggests that clinicians take into account GA results when recommending chemotherapy and that the information be provided to patients and caregivers to guide treatment decision making. Clinicians should implement targeted, GA-guided interventions to manage nononcologic problems. Additional information is available at www.asco.org/supportive-care-guidelines .

PubMed Disclaimer

Similar articles

Cited by

References

    1. Schnipper LE, Smith TJ, Raghavan D, et al. : American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 30:1715-1724, 2012 - PubMed
    1. Hurria A, Levit LA, Dale W, et al. : Improving the Evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J Clin Oncol 33:3826-3833, 2015 - PubMed
    1. Smith BD, Smith GL, Hurria A, et al. : Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 27:2758-2765, 2009 - PubMed
    1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2017. CA Cancer J Clin 67:7-30, 2017 - PubMed
    1. Hurria A, Dale W, Mooney M, et al. : Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol 32:2587-2594, 2014 - PMC - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources